Hepatic tumours and radiotherapy.

{"article_title":"Hepatic tumours and radiotherapy.","author":"Rio E, Mornex F, Maingon P, Peiffert D, Parent L","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"266","page_count":"","accession_number":"34953707","doi":"10.1016\/j.canrad.2021.08.013","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Carcinoma, Hepatocellular radiotherapy; Liver Neoplasms radiotherapy; Carcinoma, Hepatocellular pathology; Carcinoma, Hepatocellular secondary; France; Humans; Liver radiation effects; Liver Neoplasms pathology; Liver Neoplasms secondary; Organ Motion; Organs at Risk; Patient Positioning methods; Radiation Oncology; Radiosurgery methods; Radiotherapy Dosage; Radiotherapy, Conformal methods; Radiotherapy, Image-Guided; Respiration; Tumor Burden","interest_area":["Gastroenterology"," Oncology"],"abstract":"We present the update of the recommendations of the French society of oncological radiotherapy on hepatic tumours. Recent technological progress led to develop the concept of focused liver radiation therapy. We must distinguish primary and secondary tumours, as the indications are restricted and must be discussed as an alternative to surgical or medical treatments. The tumour volume, its liver location close to the organs at risk determine the irradiation technique (repositioning method, total dose delivered, dose fractionation regimens). Tumour (and liver) breathing related motions should be taken into account. Strict dosimetric criteria must be observed with particular attention to the dose-volume histograms of non-tumoral liver as well as of the hollow organs, particularly in case of hypofractionated high dose radiotherapy \"under stereotaxic conditions\". Stereotactic body radiotherapy is being evaluated and is often preferred to radiofrequency for primary or secondary tumours (usually less than 5cm). An adaptation can be proposed, with a conformal fractionated irradiation protocol with or without intensity modulation, for hepatocellular carcinomas larger than 5cm. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953707","isPdfLink":false,"isSAML":false,"an":"34953707","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 266-271. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"We present the update of the recommendations of the French society of oncological radiotherapy on hepatic tumours. Recent technological progress led to develop the concept of focused liver radiation therapy. We must distinguish primary and secondary tumours, as the indications are restricted and must be discussed as an alternative to surgical or medical treatments. The tumour volume, its liver location close to the organs at risk determine the irradiation technique (repositioning method, total dose delivered, dose fractionation regimens). Tumour (and liver) breathing related motions should be taken into account. Strict dosimetric criteria must be observed with particular attention to the dose-volume histograms of non-tumoral liver as well as of the hollow organs, particularly in case of hypofractionated high dose radiotherapy "under stereotaxic conditions". Stereotactic body radiotherapy is being evaluated and is often preferred to radiofrequency for primary or secondary tumours (usually less than 5cm). An adaptation can be proposed, with a conformal fractionated irradiation protocol with or without intensity modulation, for hepatocellular carcinomas larger than 5cm.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34953707&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Rio E, Mornex F, Maingon P, Peiffert D, Parent L"}